INMB Q4 2024 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$35M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$9M

Net Income

-$9M

EPS (Diluted)

$-0.41

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$40M

Total Liabilities

$7M

Stockholders' Equity

$32M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$28,000	-100.0%
Gross Profit	$0	$28,000	-100.0%
Operating Income	-$9M	-$8M	-13.0%
Net Income	-$9M	-$8M	-9.6%